Ovid Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OVID research report →
Range $5 – $8
Price Chart
About the company
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy.
- CEO
- Margaret Alexander
- IPO
- 2017
- Employees
- 23
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on OVID
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $442.34M
- P/E
- -4.94
- PEG
- 0.14
- P/S
- 279.43
- P/B
- 0.83
- EV/EBITDA
- -12.44
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -3686.67%
- Net Margin
- -2178.90%
- ROE
- -23.64%
- ROIC
- -26.11%
Latest fiscal year · YoY change
- Revenue
- $7.25M+1181.3%
- Gross Profit
- $6.95M+1128.3%
- Op Income
- $-42,439,000
- Net Income
- $-17,414,000+34.1%
- EPS
- $-0.24+35.1%
- OCF Growth
- +31.5%
- FCF Growth
- +31.6%
- 52W High
- $3.11
- 52W Low
- $1.18
- 50D MA
- $2.64
- 200D MA
- $2.30
- Beta
- 0.23
- RSI (14)
- 37
- Avg Volume
- 1.63M
No earnings-call transcripts are available for OVID yet.
- Free Float
- 82.5%
- Shares Outstanding
- 186.64M
- Float Shares
- 154.02M
of shares held by institutions
109 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 20.74M | ▲ 20.74M |
| Eventide Asset Management, LLC | 11.81M | ▲ 1.90M |
| Blackrock, Inc. | 10.82M | ▲ 9.29M |
| Janus Henderson Group Ltd. | 10.71M | ▲ 10.71M |
| Ra Capital Management, L.P. | 10.50M | ▼ 213.03K |
| Affinity Asset Advisors, LLC | 10.14M | ▼ 491.76K |
| State Street Corp | 7.90M | ▲ 7.38M |
| Vanguard Capital Management LLC | 7.76M | ▲ 2.50M |
| Takeda Pharmaceutical Co Ltd | 7.53M | 0 |
| Adar1 Capital Management, LLC | 7.42M | ▲ 2.87M |
| Balyasny Asset Management L.P. | 6.72M | ▲ 1.19M |
| Adage Capital Partners Gp, L.L.C. | 6.16M | 0 |
Held by 121 ETFs
Biggest fund positions in OVID by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 6, 26 | Carter Charles Ross | other | 50,000 |
| Jul 6, 26 | Carter Charles Ross | other | 0 |
| Jul 6, 26 | Carter Charles Ross | other | 200,000 |
| Jul 6, 26 | Carter Charles Ross | other | 206,250 |
| Jun 15, 26 | Greka Anna | other | 130,000 |
| Jun 15, 26 | Greka Anna | other | 0 |
| Apr 7, 26 | PAPADOPOULOS STELIOS | other | 17,578 |
| Apr 7, 26 | Friedman Bart | other | 8,789 |
| Apr 7, 26 | Fitzgerald Kevin Joseph | other | 17,578 |
| Mar 23, 26 | LEVIN JEREMY M | other | 47,333 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OVID coverage
Recent articles, reports, and earnings notes.
No research on OVID yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OVID report →Ovid Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 3
BlackRock Inc. Takes Position in Ovid Therapeutics $OVID
defenseworld.net · Sep 2
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
zacks.com · Aug 18
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
zacks.com · Aug 13
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
globenewswire.com · Aug 13
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
zacks.com · Aug 5
Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID
defenseworld.net · Jul 29
ADAR1 Capital Management LLC Acquires 259,113 Shares of Ovid Therapeutics $OVID
defenseworld.net · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.